Mortality in systemic sclerosis.

Systemic sclerosis is a rare and potentially devastating connective tissue disease. It is highly heterogeneous in terms of clinical presentation, extent and severity of organ involvement, immunologic abnormalities, and clinical course. Although clinical outcomes appear to have improved in recent years, the disease continues to cause substantial excess mortality. In this review, we have systematically collected the published studies addressing the mortality burden in patients with scleroderma in comparison with the general population, as well as studies exploring the most important potential predictors of mortality. Results of these studies are presented and discussed, with emphasis on methodological limitations. Suggestions are made for the design, conduct, and reporting of further research on these themes.

[1]  J. Ioannidis.  Why Most Discovered True Associations Are Inflated , 2008, Epidemiology.

[2]  L. Czirják,et al.  Survival and causes of death in 366 Hungarian patients with systemic sclerosis , 2007, Annals of the rheumatic diseases.

[3]  E. Chakravarty,et al.  Hospitalizations and mortality in systemic sclerosis: results from the Nationwide Inpatient Sample. , 2007, Rheumatology.

[4]  John P A Ioannidis,et al.  Almost all articles on cancer prognostic markers report statistically significant results. , 2007, European journal of cancer.

[5]  F. Mendoza,et al.  Systemic Sclerosis Mortality in the United States: 1999–2002 Implications for Patient Care , 2007, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[6]  T. Medsger,et al.  Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. , 2007, Arthritis and rheumatism.

[7]  Mark Lunt,et al.  Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. , 2007, Arthritis and rheumatism.

[8]  D. Hansell,et al.  Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. , 2007, Arthritis and rheumatism.

[9]  David Abraham,et al.  Systemic sclerosis: a prototypic multisystem fibrotic disorder. , 2007, The Journal of clinical investigation.

[10]  T. Medsger,et al.  Changes in causes of death in systemic sclerosis, 1972–2002 , 2007, Annals of the rheumatic diseases.

[11]  J. Ioannidis,et al.  Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. , 2007, Journal of the National Cancer Institute.

[12]  J. Ioannidis,et al.  Patient Outcomes with Teaching Versus Nonteaching Healthcare: A Systematic Review , 2006, PLoS medicine.

[13]  D. Furst,et al.  Systemic sclerosis: hypothesis-driven treatment strategies , 2006, The Lancet.

[14]  P. Grenier,et al.  Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. , 2006, Arthritis and rheumatism.

[15]  S. Jimenez,et al.  Morbidity and mortality of patients diagnosed with systemic sclerosis after the age of 75: a nested case-control study , 2006, Clinical Rheumatology.

[16]  F. Wollheim.  Classification of systemic sclerosis. Visions and reality. , 2005, Rheumatology.

[17]  B. Tilley,et al.  Demographic and clinical factors associated with in-hospital death among patients with systemic sclerosis. , 2005, The Journal of rheumatology.

[18]  John P A Ioannidis,et al.  Selective reporting biases in cancer prognostic factor studies. , 2005, Journal of the National Cancer Institute.

[19]  D. Altman,et al.  Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors , 2005, BMJ : British Medical Journal.

[20]  J. Ioannidis,et al.  Mortality in systemic sclerosis: an international meta-analysis of individual patient data. , 2005, The American journal of medicine.

[21]  D. Furst,et al.  Systemic Sclerosis Mortality in the United States: 1979–1998 , 2005, European Journal of Epidemiology.

[22]  S. Jimenez,et al.  Following the Molecular Pathways toward an Understanding of the Pathogenesis of Systemic Sclerosis , 2004, Annals of Internal Medicine.

[23]  C. Denton,et al.  Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach , 2003, Annals of the rheumatic diseases.

[24]  Brenda W Gillespie,et al.  Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. , 2003, Arthritis and rheumatism.

[25]  J. Vaqué,et al.  Mortality and prognostic factors in Spanish patients with systemic sclerosis. , 2003, Rheumatology.

[26]  W. Louthrenoo,et al.  Causes of death and poor survival prognostic factors in thai patients with systemic sclerosis. , 2002, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[27]  Ethan A Halm,et al.  Is Volume Related to Outcome in Health Care? A Systematic Review and Methodologic Critique of the Literature , 2002, Annals of Internal Medicine.

[28]  S. Bombardieri,et al.  Systemic Sclerosis: Demographic, Clinical, and Serologic Features and Survival in 1,012 Italian Patients , 2002, Medicine.

[29]  É. Rich,et al.  Predicting Mortality in Systemic Sclerosis: Analysis of a Cohort of 309 French Canadian Patients with Emphasis on Features at Diagnosis as Predictive Factors for Survival , 2002, Medicine.

[30]  T. Medsger,et al.  Improvement in skin thickening in systemic sclerosis associated with improved survival. , 2001, Arthritis and rheumatism.

[31]  F. Wollheim,et al.  Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale , 2001, Annals of the rheumatic diseases.

[32]  A. Wiik,et al.  Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. , 2001, The Journal of rheumatology.

[33]  T. Medsger,et al.  Criteria for the classification of early systemic sclerosis. , 2001, The Journal of rheumatology.

[34]  F. Wigley.  When is scleroderma really scleroderma? , 2001, The Journal of rheumatology.

[35]  C. Denton,et al.  Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. , 2001, Rheumatology.

[36]  Richard W. Martin,et al.  Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. , 2000, Arthritis and rheumatism.

[37]  T. Medsger,et al.  Severe organ involvement in systemic sclerosis with diffuse scleroderma. , 2000, Arthritis and rheumatism.

[38]  T. Medsger,et al.  Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. , 2000, Arthritis and rheumatism.

[39]  A. Silman,et al.  Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. , 1999, Arthritis and rheumatism.

[40]  A. Silman,et al.  A disease severity scale for systemic sclerosis: development and testing. , 1999, The Journal of rheumatology.

[41]  R. Hesselstrand,et al.  Mortality and causes of death in a Swedish series of systemic sclerosis patients , 1998, Annals of the rheumatic diseases.

[42]  S. Ullman,et al.  Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma) , 1998, British journal of rheumatology.

[43]  A. Wiik,et al.  Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. , 1998, British journal of rheumatology.

[44]  A. Silman,et al.  Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. , 1996, British journal of rheumatology.

[45]  K. Nishioka,et al.  Epidemiological Analysis of Prognosis of 496 Japanese Patients with Progressive Systemic Sclerosis (SSc) , 1996, The Journal of dermatology.

[46]  M. Abu-Shakra,et al.  Mortality in systemic sclerosis: a comparison with the general population. , 1995, The Journal of rheumatology.

[47]  M. Kuwana,et al.  Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. , 1994, Arthritis and rheumatism.

[48]  P. Lachenbruch,et al.  Early Undifferentiated Connective Tissue Disease: III. Outcome and Prognostic Indicators in Early Scleroderma (Systemic Sclerosis) , 1993, Annals of Internal Medicine.

[49]  Y. Ikeda,et al.  Initial predictors of survival in patients with systemic sclerosis (scleroderma). , 1992, The Keio journal of medicine.

[50]  D. Buskila,et al.  Mortality in systemic sclerosis (scleroderma). , 1992, The Quarterly journal of medicine.

[51]  D. Bloch,et al.  Predictors of survival in systemic sclerosis (scleroderma). , 1991, Arthritis and rheumatism.

[52]  A. Silman.  Scleroderma and survival. , 1991, Annals of the rheumatic diseases.

[53]  M. Weinrich,et al.  Prevalence of scleroderma spectrum disorders in the general population of South Carolina. , 1989, Arthritis and rheumatism.

[54]  Brokhaug Ak.  Visions and reality , 1989 .

[55]  T. Medsger,et al.  Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. , 1988, Arthritis and rheumatism.

[56]  T. Medsger,et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.

[57]  G. Littlejohn,et al.  A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease. , 1988, The Journal of rheumatology.

[58]  N. Fineberg,et al.  Prediction of survival in progressive systemic sclerosis by multivariate analysis of clinical features. , 1985, American heart journal.

[59]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[60]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.

[61]  N. Rowell.  The prognosis of systemic sclerosis , 1974, The British journal of dermatology.

[62]  A. Masi,et al.  Survival with scleroderma. II. A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients. , 1973, Journal of chronic diseases.

[63]  P. Holt,et al.  Survival in scleroderma. , 1971, Annals of the rheumatic diseases.

[64]  A. Masi,et al.  Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. , 1971, Annals of internal medicine.

[65]  R. Winkelmann,et al.  Systemic scleroderma, A clinical study of 727 cases. , 1961, Archives of dermatology.

[66]  E. Hines,et al.  Prognostic Significance of Raynaud's Phenomenon and Other Clinical Characteristics of Systemic Scleroderma: A Study of 271 Cases , 1960, Circulation.